Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema

Yu, Seung-Young; Nam, Dong Heun; Lee, Dae Yeong

doi:10.1007/s00417-017-3819-2

Cited by 21 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aqueous humor levels of VEGF, IL-8 and MCP-1 were consistently increased in patients with DME (Roh et al, 2009;Funk et al, 2010;Sohn et al, 2011;Jonas et al, 2012;Yu et al, 2018) whereas results regarding other cytokines are more variable.…”

Section: Levels Of Cytokines In Diabetic Macular Edemamentioning

confidence: 92%

“…IL-6 is also increased in DME patients (Roh et al, 2009;Jonas et al, 2012;Wen et al, 2015), although some studies did not show a statistically significant difference (Sohn et al, 2011;Yu et al, 2018).…”

Section: Levels Of Cytokines In Diabetic Macular Edemamentioning

confidence: 98%

“…Platelet-derived growth factor (PDGF), which is expressed in platelets, fibroblasts and other cell types, promotes cellular proliferation and guides cellular movement (Yu et al, 2018).…”

Section: Growth Factorsmentioning

confidence: 99%

“…As far as we know, there are five different studies comparing cytokine levels after treatment with bevacizumab (Roh et al, 2009;Funk et al, 2010;Sohn et al, 2011;Wen et al, 2015;Yu et al, 2018), two studies with ranibizumab (Shiraya et al, 2017;Hillier et al, 2018) and only one study analyses cytokine levels after treatment with intravitreal aflibercept (Mastropasqua et al, 2018). Furthermore, one study evaluated cytokine level variation after treatment with triamcinolone and another study after combined treatment with triamcinolone plus bevacizumab (table 2).…”

Section: Jpet # 262956mentioning

confidence: 99%

See 3 more Smart Citations

Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

Torres-Costa

Valente

Falcão‐Reis

et al. 2020

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Anti-vascular endothelial growth factors (anti-VEGF) agents are efficient as DME treatment. However, in some cases, DME fails to respond to anti-VEGF intravitreal injections. Changes in cytokine levels after treatment supported the idea that other cytokines than VEGF are implicated in DME pathogenesis and could be predictors of response to anti-VEGF treatment or corticosteroids allowing targeted and individualized therapy guided by cytokine levels.

show abstract

Section: Levels Of Cytokines In Diabetic Macular Edemamentioning

confidence: 92%

Section: Levels Of Cytokines In Diabetic Macular Edemamentioning

confidence: 98%

“…Platelet-derived growth factor (PDGF), which is expressed in platelets, fibroblasts and other cell types, promotes cellular proliferation and guides cellular movement (Yu et al, 2018).…”

Section: Growth Factorsmentioning

confidence: 99%

Section: Jpet # 262956mentioning

confidence: 99%

See 2 more Smart Citations

Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

Torres-Costa

Valente

Falcão‐Reis

et al. 2020

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…; Yu et al. ). Aqueous and serum cytokine levels seem to be elevated in patients with DME and decrease under treatment with intravitreal bevacizumab or triamcinolone in a short follow‐up time of one month (Sohn et al.…”

Section: Introductionmentioning

confidence: 97%

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema

Podkowinski

Orlowski‐Wimmer

Zlabinger

et al. 2019

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To determine the effect of intravitreal ranibizumab and a dexamethasone implant on aqueous humour cytokine, protein and enzyme levels and to correlate findings to morphologic and functional changes. Methods: In a prospective, randomized, controlled, double-blind study, patients with clinically significant diabetic macular oedema (CSME) were randomly allocated to receive either monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma) or a single dexamethasone implant (Ozurdex, Pharm-Allergan) at baseline (BL). Aqueous humour samples were collected at BL and weeks 2, 8 and 20. Results: The study included 18 eyes of 18 patients. In the dexamethasone implant group, soluble intercellular adhesion molecule 1 (sICAM-1) (weeks 2 and 8), CXCL9/monokine induced by gamma interferon (MIG) (weeks 2 and 8), soluble vascular cell adhesion protein 1 (sVCAM-1) (weeks 2 and 8) and monocyte chemo-attractant protein 1 (MCP-1) (week 2) levels were significantly decreased compared with baseline. In the ranibizumab group, placental growth factor (PIGF) (week 2) and vascular endothelial growth factor (VEGF) (week 2 and 8) levels were significantly decreased compared with baseline. No significant changes in central retinal thickness (CRT) or Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) were observed in the Ozurdex group at any time-points. ETDRS scores significantly increased at week 20 (84.88 AE 8.88 letters) compared with baseline (74.78 AE 14.85 letters), and the CRT decreased significantly at week 4 (381.00 AE 114.64 lm) compared with baseline (440 AE 144 lm) in the Lucentis group. Conclusion: The dexamethasone implant affected the aqueous cytokines and proteins MCP-1, sICAM-1, sVCAM-1 and MIG, whereas ranibizumab treatments reduced VEGF and PIGF levels. Morphological changes may diverge from cytokine changes. Results may indicate a rationale for a combination therapy for CSME using both agents, the dexamethasone implant and repeatedly administered ranibizumab injections.

show abstract

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema

Mehta

Hennings

Gillies

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Combination of intravitreal anti-VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. The majority of the evidence comes from studies of bevacizumab and triamcinolone used as primary therapy for DMO. There is limited evidence from studies using licensed intravitreal anti-VEGF agents plus licensed intravitreal steroid implants with at least one year follow-up. It is not known whether treatment response is different in eyes that are phakic and pseudophakic at baseline.

show abstract

Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema

Abstract: Intravitreal bevacizumab and subtenon triamcinolone injection reduces the VEGF, MCP-1 and PDGF-AA levels and increases the IL-8 level in the plural cytokine profiles of patients with DME, which might explain the limited therapeutic effect of combination therapy.

Cited by 21 publications

References 33 publications

Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema

Contact Info

Product

Resources

About